Published 11 days ago • loading... • Updated 11 days ago
Aspen Aerogels: Green Shoots Fail To Truly Impress Investors (NYSE:ASPN)
Q2 revenue topped guidance as thermal barrier sales recovered and the company lowered its annual EBITDA break-even threshold to $175 million, analysts said.
Summary
Aspen Aerogels stock is a "Hold" but its Q3 outlook shows recovery as revenues/EBITDA improve and break-even drops. Click here to learn more about ASPN.